Overview
QuidelOrtho reports Q3 revenue of $700 mln, beating analysts' expectations
Adjusted EPS beats consensus, reflecting effective cost-savings initiatives
Company reports goodwill impairment charge of $701 mln, impacting GAAP net loss
Outlook
QuidelOrtho sees full-year 2025 revenue between $2.68 bln and $2.74 bln
Company expects full-year 2025 adjusted EBITDA of $585 mln to $605 mln
QuidelOrtho forecasts full-year 2025 adjusted EPS between $2.00 and $2.15
Result Drivers
REVENUE DECLINE - Total revenue decreased 4% due to lower COVID-19 and Donor Screening revenue
COST-SAVINGS INITIATIVES - Decreased operating expenses and improved adjusted EBITDA margin attributed to cost-savings measures
DEBT REFINANCING - Successful debt refinancing improved financial flexibility through better terms and reduced obligations
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $699.9 mln | $664.96 mln (8 Analysts) |
Q3 Adjusted EPS | Beat | $0.80 | $0.46 (7 Analysts) |
Q3 EPS | -$10.78 | ||
Q3 Net Income | -$733 mln | ||
Q3 Basic EPS | -$10.78 | ||
Q3 Operating Income | -$704.8 mln |
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 4 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."
Wall Street's median 12-month price target for QuidelOrtho Corp is $34.00, about 20.2% above its November 4 closing price of $27.13
The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 8 three months ago
Press Release: ID:nPn9KJl95a
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)